Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) remains a significant clinical challenge.
• Androgen receptor (AR) signaling is a primary driver in most prostate cancers, but resistance mechanisms emerge.
• A subset of mCRPC exhibits resistance to AR-targeted therapies, necessitating the identification of alternative drivers.

Purpose of the Study:

• To investigate the molecular mechanisms driving AR pathway-independent growth in a subset of mCRPC.
• To identify potential therapeutic targets for mCRPC that does not rely on AR signaling.

Main Methods:

• Analysis of tumor samples from patients with metastatic castration-resistant prostate cancer.
• Gene expression profiling to identify molecular subtypes.
• Functional assays to assess signaling pathway activation and dependency.

Main Results:

• Identified a subset of mCRPC (approximately 20%) that lacks expression of AR and neuroendocrine genes.
• Demonstrated that this AR-independent mCRPC subset exhibits growth driven by a FGFR/MAPK/ID1 signaling cascade.
• Showcased AR pathway-independent tumor growth.

Conclusions:

• A distinct molecular subtype of mCRPC exists, characterized by AR pathway independence.
• The FGFR/MAPK/ID1 pathway represents a critical driver in this AR-independent mCRPC subset.
• Co-targeting AR bypass pathways alongside initial AR antagonism may be a rational therapeutic strategy for specific mCRPC patients.